{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:59:42Z","timestamp":1782763182279,"version":"3.54.5"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.cardfail.2016.04.009","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T18:40:36Z","timestamp":1462041636000},"page":"439-448","source":"Crossref","is-referenced-by-count":40,"title":["Heart Failure Therapies for End-Stage Chemotherapy\u2013Induced Cardiomyopathy"],"prefix":"10.1016","volume":"22","author":[{"given":"Roy B.","family":"Mukku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol E.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olujimi A.","family":"Ajijola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene C.","family":"Depasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nsair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario C.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-7454","authenticated-orcid":false,"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2016.04.009_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0025","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCHEARTFAILURE.114.001292","article-title":"Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy","volume":"7","author":"Oliveira","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.healun.2012.03.018","article-title":"Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation","volume":"31","author":"Oliveira","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","article-title":"Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics","volume":"106","author":"Cheng","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0040","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0045","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0055","first-page":"1287","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0060","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cardfail.2013.12.018","article-title":"Cancer therapy\u2013induced left ventricular dysfunction: interventions and prognosis","volume":"20","author":"Thakur","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0080","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0085","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.1984.2.3.207","article-title":"Increased therapeutic index of weekly doxorubicin in the therapy of non\u2013small cell lung cancer: a prospective, randomized study","volume":"2","author":"Valdivieso","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0100","first-page":"223","article-title":"Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet","volume":"7","author":"Gabizon","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0110","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","article-title":"Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol","volume":"20","author":"Lipshutz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0115","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0120","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0125","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0135","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0140","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II\u03b2\u2013mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.cardfail.2016.04.009_bib0145","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0150","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0155","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0160","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0165","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0170","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0175","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0185","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","article-title":"Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0190","first-page":"115","article-title":"Beta-blockade in adriamycin-induced cardiomyopathy","volume":"6","author":"Noori","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0195","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0200","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinal","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0205","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0210","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0215","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0220","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0225","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0230","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.healun.2007.09.003","article-title":"Cardiac re-synchronization therapy in a child with severe anthracycline-induced congestive heart failure and normal QRS duration","volume":"26","author":"Jones","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0235","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ijcard.2008.11.194","article-title":"Anthracycline-induced cardiomyopathy: favourable effects of cardiac resynchronization therapy","volume":"142","author":"Ahlehoff","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0240","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.amjcard.2007.12.037","article-title":"Usefulness of cardiac resynchronization therapy in the management of doxorubicin-induced cardiomyopathy","volume":"101","author":"Ajijola","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0245","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.amjcard.2009.10.024","article-title":"Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy","volume":"105","author":"Rickard","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0255","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.healun.2015.10.003","article-title":"Seventh INTERMACS annual report: 15,000 patients and counting","volume":"34","author":"Kirklin","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0260","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jacc.2015.03.036","volume":"19","author":"Rihal","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0265","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1067\/mtc.2001.114351","article-title":"Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years","volume":"122","author":"Smedira","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0270","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/j.healun.2013.01.318","article-title":"Outcomes of heart transplant (HT) recipients bridged with ECMO","volume":"32","author":"DePasquale","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0275","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MAT.0000000000000309","article-title":"Clinical outcomes of advanced heart failure patients with cardiogenic shock treated with temporary circulatory support before durable LVAD implant","volume":"62","author":"Shah","year":"2016","journal-title":"ASAIO J"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0280","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","article-title":"Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support)","volume":"63","author":"Oliveira","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0285","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.healun.2012.09.018","article-title":"Outcomes of adults with restrictive cardiomyopathy after heart transplantation","volume":"31","author":"DePasquale","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0290","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/ctrv.1999.0128","article-title":"Detection of anthracycline-induced cardiotoxicity","volume":"25","author":"Meinardi","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0295","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jacc.2007.09.008","volume":"50","author":"Cooper","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0305","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.cardfail.2010.07.082","article-title":"A case of adriamycin-induced cardiomyopathy implanted artificial heart after having the uncontrollable arrhythmia","volume":"16","author":"Hayashi","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0310","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.healun.2015.12.001","article-title":"Chronic biventricular HVAD support\u2014case series of right atrial and right ventricular implantation outcomes","volume":"35","author":"Shehab","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0315","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1542\/peds.2013-2272","article-title":"VAD as bridge to recovery in anthracycline-induced cardiomyopathy and HHV6 myocarditis","volume":"134","author":"Cavigelli-Brunner","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0320","first-page":"554","article-title":"Remission of chronic anthracycline-induced heart failure with support from a continuous-flow left ventricular assist device","volume":"39","author":"Khan","year":"2012","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0325","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1751-7133.2012.00291.x","article-title":"Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure","volume":"18","author":"Appel","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0330","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14503\/THIJ-14-4509","article-title":"Anthracycline treatment and ventricular remodeling in left ventricular assist device patients","volume":"42","author":"Segura","year":"2015","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0335","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa040186","article-title":"Cardiac replacement with a total artificial heart as a bridge to transplantation","volume":"351","author":"Copeland","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0340","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.transproceed.2015.04.083","article-title":"Total artificial heart bridge to transplantation for a patient with occult intracardiac malignancy: case report","volume":"47","author":"Reich","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0350","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.healun.2015.08.003","article-title":"The Registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplantation report\u20142015; focus theme: early graft failure","volume":"34","author":"Lund","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0355","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0140-6736(05)80084-4","article-title":"Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients","volume":"342","author":"Opelz","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/CIRCULATIONAHA.109.858076","article-title":"Selection of cardiac transplantation candidates in 2010","volume":"122","author":"Mancini","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0365","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 ISHLT listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0375","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-2007-1016470","article-title":"Successful long-term course after heart transplantation for anthracycline cardiomyopathy in a young boy despite neurological complications","volume":"42","author":"Deng","year":"1994","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0380","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.amjcard.2012.10.048","article-title":"Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy","volume":"111","author":"Lenneman","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2016.04.009_bib0385","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.athoracsur.2014.06.056","article-title":"Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience","volume":"98","author":"Saxena","year":"2014","journal-title":"Ann Thorac Surg"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916416300537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916416300537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T15:41:01Z","timestamp":1657381261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916416300537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1071916416300537"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2016.04.009","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}